Kodiak Sciences says Zenkuda meets primary endpoint in Phase 3 DAYBREAK wet AMD trial
Bitget2026/09/28 10:31- Kodiak Sciences reported pivotal Phase 3 DAYBREAK trial success in wet age-related macular degeneration for Zenkuda and tabirafusp-ted.
- Both treatments matched aflibercept on vision outcomes at one year, supporting a potential path toward first-line use.
- Zenkuda showed rapid disease control with longer dosing intervals for many patients, strengthening its commercial positioning versus standard anti-VEGF therapy.
- The company plans a multi-indication Zenkuda BLA submission in 4Q2026, anchored by five positive Phase 3 studies.
- Detailed DAYBREAK results will be presented at a company Webex on Sept. 28, 2026.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
JPMorgan optimistic about renewed capital inflows into tech stocks: lower positions and falling valuations create opportunities
The JPMorgan team of strategists believes that as position crowding decreases, earnings performance remains strong, and valuations become more realistic, technology stocks will regain some of the momentum lost since mid-year. Investors are expected to re-enter the sector.
Nvidia increases stock repurchase authorization by 150 billion dollars
VinFast schedules Q2 2026 results webcast
Vestis names Russell Tiejema CFO effective Sept. 28, 2026
Crypto prices
More
